chronic lymphocytic leukemia

Type: Keyphrase
Name: chronic lymphocytic leukemia
First reported 23 hours ago - Updated 18 hours ago - 1 reports

Company Update: Biogen Idec Inc (NASDAQ:BIIB) – Biogen Idec Names Adriana Karaboutis EVP, Technology and Business Solutions

[Business Wire] – Biogen Idec today announced the appointment of Adriana Karaboutis as executive vice president, Technology and Business Solutions, effective September 24, 2014.Read more on this.Biogen Idec Inc. (BIIB) , currently valued at $81.05B, ended ... [Published Jutia Group - 23 hours ago]
First reported Aug 21 2014 - Updated Aug 21 2014 - 1 reports

New Developments in Chronic Lymphocytic Leukemia Treatment

Recently, Federal Practitioner talked with Sanjai Sharma, MD, about how signaling pathways in chronic lymphocytic leukemia (CLL) is critical to the development of therapeutic agents to treat... ... [Published Federal Practitioner - Aug 21 2014]
First reported Aug 20 2014 - Updated Aug 20 2014 - 1 reports

CLL's 'Very Unusual Year'

Dr. Bruce Cheson discusses how to choose among the new, exciting options available for the treatment of chronic lymphocytic leukemia: obinutuzumab, ibrutinib, and idelalisib.Medscape Oncology ... [Published Medscape - Aug 20 2014]
First reported Aug 17 2014 - Updated Aug 17 2014 - 1 reports

Aberrations of MYC Are a Common Event in B-Cell Prolymphocytic Leukemia. September 01, 2014

Am J Clin Pathol.2014;142(3):347-54  (ISSN: 1943-7722)Flatley E; Chen AI; Zhao X; Jaffe ES; Dunlap JB; Pittaluga S; Abdullah S; Olson SB; Spurgeon SE; Fan GOBJECTIVES:B-cell prolymphocytic leukemia (B-PLL) remains a controversial entity, and its molecular ... [Published American Journal of Clinical Pathology - Aug 17 2014]
First reported Aug 16 2014 - Updated Aug 16 2014 - 1 reports

Market Update: Biogen Idec Inc (NASDAQ:BIIB) – Biogen wins U.S. approval of long acting multiple sclerosis drug

[Reuters] – U.S. health regulators on Friday approved Biogen Idec Inc’s Plegridy, a long-acting multiple sclerosis drug that the company expects will eventually replace its older big-selling Avonex treatment. The …Read more on this.Biogen Idec Inc. (BIIB) ... [Published Jutia Group - Aug 16 2014]
First reported Aug 15 2014 - Updated Aug 15 2014 - 1 reports

ZYDELIG® (idelalisib) for Relapsed Chronic Lymphocytic Leukemia

This slideshow reviews drug information for ZYDELIG® (idelalisib), indicated for relapsed chronic lymphoma.Table of ContentsSlide 3: Indication, Dosage, and AdministrationSlide 7: Use in Specific PopulationsSlide 9: Clinical PharmacologySlide 13: Warnings ... [Published Chemotherapy Advisor - Aug 15 2014]
First reported Jul 31 2014 - Updated Jul 31 2014 - 3 reports

Pharmacyclics Reports Second Quarter 2014 Results

/PRNewswire/ -- Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) today reported financial results and recent developments for the quarter ended June 30, 2014.Financial Results for the Six Months and Quarter Ended June 30, 2014 RevenueTotal revenue for ... [Published Bio-Medicine - Jul 31 2014]
First reported Jul 29 2014 - Updated Jul 30 2014 - 5 reports

Roche gets European approval for leukemia treatment Gazyvaro

Swiss health-care firm Roche has received approval from the European Commission for Gazyvaro (obinutuzumab) in combination with chlorambucil chemotherapy to treat people with previously untreated chronic lymphocytic leukemia (CLL) who have comorbidities ... [Published PBR - News - Jul 30 2014]
First reported Jul 28 2014 - Updated Jul 29 2014 - 11 reports

FDA Expands Approved Use of Imbruvica for Chronic Lymphocytic Leukemia

-- The U.S. Food and Drug Administration today expanded the approved use of Imbruvica (ibrutinib) to treat patients with chronic lymphocytic leukemia (CLL) who carry a deletion in chromosome 17 (17p deletion), which is associated with... ... [Published Drugs.com - Jul 29 2014]
First reported Jul 25 2014 - Updated Jul 25 2014 - 5 reports

European CHMP Adopts Positive Opinion for Gilead’s Zydelig® (idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma

European CHMP Adopts Positive Opinion for Gilead’s Zydelig® (idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma ... [Published Nasdaq - Jul 25 2014]
First reported Jul 24 2014 - Updated Jul 25 2014 - 3 reports

FDA approves idelalisib for the treatment of patients with relapsed chronic lymphocytic leukemia

The U.S. Food and Drug Administration (FDA) has approved idelalisib (Zydelig tablets, GileadSciences, Inc.) for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL), in combination with rituximab, for whom rituximab alone would be ... [Published Ecancer Medicalscience - Jul 25 2014]
First reported Jul 23 2014 - Updated Jul 24 2014 - 10 reports

FDA Approves New Cancer Medication

Zydelig approved to treat certain blood cancersJuly 23, 2014 / Author: / Reviewed by: Joseph V. Madia, MDRate This ArticleAverage Rating3.85Your Rating(dailyRx News) The US Food and Drug Administration (FDA) approved Zydelig (idelalisib) today to treat ... [Published Daily Rx - Jul 24 2014]

Quotes

Michael Cardone , Ph DD CEO of Eutropics added, "The predictive diagnostic demonstrated in this new study provides the promise of speeding clinical validation of an important new drug and could provide immediate positive impact on patient care."
...As CEO Alex Gorsky noted in J&J's earnings release, "Our strong second-quarter results reflect the continued success of our new product launches and the progress we have made in achieving our near-term priorities."
" Roche recognizes that patients and patient organizations are playing an increasingly important role in drug review and health technology assessment and bring valuable experience, perspective and insight to the process. As an organization committed to patients, Roche is pleased to participate in this Health Canada pilot program that is seeking patient input within the regulatory review process" said Lorenzo Biondi Vice President, Medical & Regulatory Affairs, Hoffmann-La Roche Limited
"Gilead Sciences Inc., a research-based biopharmaceutical company, is engaged in the discovery, development, and commercialization of medicines in areas of unmet medical need. The company has operations in North and South America, Europe and Asia-Pacific."

More Content

All (435) | News (334) | Reports (0) | Blogs (87) | Audio/Video (0) | Fact Sheets (1) | Press Releases (11)
sort by: Date | Relevance
Pharma ETF Investing 101 [Published Yahoo! Finance - 18 hours ago]
FDA Red Tape Blocks Effective Treatments [Published NewsMax.com - 18 hours ago]
Company Update: Biogen Idec Inc (NASDAQ:BIIB) –... [Published Jutia Group - 23 hours ago]
New Developments in Chronic Lymphocytic Leukemi... [Published Federal Practitioner - Aug 21 2014]
CLL's 'Very Unusual Year' [Published General Medicine eJournal - Aug 20 2014]
Tolero Pharmaceuticals and Eutropics Announce D... [Published HispanicBusiness.com - Aug 20 2014]
CLL's 'Very Unusual Year' [Published Medscape - Aug 20 2014]
Three Biotech Companies With Disruptive UPenn T... [Published Benzinga.com - Aug 19 2014]
Bionomics 2013/2014 Preliminary Final Results [Published Noodls - Aug 19 2014]
3 Reasons Johnson & Johnson Stock Could Rise [Published Motley Fool Discussion Boards - Aug 18 2014]
Copy Number Variation Analysis on a Non-Hodgkin... [Published Plosone.org - Aug 18 2014]
Researcher Honored for Lifetime Achievement in ... [Published India-West - Aug 18 2014]
Ronald Fischer: Measure 1 reaffirms your right ... [Published Grand Forks Herald - Aug 17 2014]
Aberrations of MYC Are a Common Event in B-Cell... [Published American Journal of Clinical Pathology - Aug 17 2014]
HYPERION THERAPEUTICS : Patient Involvement Pil... [Published 4 Traders - Aug 16 2014]
Market Update: Biogen Idec Inc (NASDAQ:BIIB) – ... [Published Jutia Group - Aug 16 2014]
Why Gilead Is The Most Exciting Growth Opportun... [Published Seeking Alpha - Aug 15 2014]
ZYDELIG® (idelalisib) for Relapsed Chronic Lymp... [Published Chemotherapy Advisor - Aug 15 2014]
Ibrutinib in Previously Treated CLL and CLL Wit... [Published The ASCO Post - Aug 15 2014]
TG Therapeutics Announces Novel "Chemo-free" Tr... [Published GlobeNewswire: Earnings News - Aug 15 2014]
Idelalisib for Relapsed CLL in Combination With... [Published The ASCO Post - Aug 15 2014]
The End of FDA Paternalism? [Published Policy Review - Aug 15 2014]
OVERNIGHT CAMPAIGN: 2016 hopefuls weigh in on F... [Published The Hill - Aug 14 2014]
Adam Kwasman Announces He Has Blood Cancer [Published KNAU - Aug 14 2014]
Genmab Announces Financial Results for the Firs... [Published Pharmacy Choice - Aug 14 2014]
Arizona congressional candidate says he has cancer [Published KTAR.com - Aug 14 2014]
Health Canada's Orphan Drug Pilot Project Seeks... [Published FDA News - Aug 14 2014]
INFINITY PHARMACEUTICALS : Amends PI3K-Delta, G... [Published 4 Traders - Aug 14 2014]
Bull of the Day: Gilead Sciences (GILD) - Bull ... [Published Benzinga.com - Aug 13 2014]
Genmab Announces Financial Results for the Firs... [Published Virtual Strategy Magazine - Aug 13 2014]
1 2 3 4 5 6 7 8 9 10 ...
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Tolero Pharmaceuticals and Eutropics Announce D... [Published Business Wire Health News - Aug 12 2014]
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Eutropics, Inc, (Cambridge, MA) and Tolero Pharmaceuticals, Inc, (Lehi, UT) announced today that clinical study results demonstrating a predictive biomarker for Chronic Lymphocytic Leukemia (CLL) patient response to ...
The Top 5 Worst Corporate Citizens in the U.S. [Published Wall St. Cheat Sheet - Aug 11 2014]
Jeff Vinnick/Getty Images Corporate Responsibility Magazine regularly publishes a list of the top 100 Best Corporate Citizens . Using a robust set of data, CR Magazine identifies which corporations are the most socially, environmentally, and ethically ...
Infinity Reports Second Quarter 2014 Financial ... [Published EON Science - Aug 05 2014]
CAMBRIDGE, Mass.--(EON: Enhanced Online News)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced its second quarter 2014 financial results and ongoing progress with IPI-145, an oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma. ...
Infinity Reports Second Quarter 2014 Financial ... [Published Business Wire Science: Science News - Aug 05 2014]
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced its second quarter 2014 financial results and ongoing progress with IPI-145, an oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma. “Over ...
Infinity Reports Second Quarter 2014 Financial ... [Published Business Wire Health News - Aug 05 2014]
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced its second quarter 2014 financial results and ongoing progress with IPI-145, an oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma. “Over ...
1 2 3 4 5 6 7 8 9 10 ...

Press Releases

sort by: Date | Relevance
TG Therapeutics Announces Novel "Chemo-free" Tr... [Published GlobeNewswire: Earnings News - Aug 15 2014]
TG Therapeutics' Novel Combination of TG-1101 (... [Published GlobeNewswire: Advertising News - Jul 21 2014]
GSK and Genmab Receive EU Authorization for Arz... [Published GlobeNewswire: Nutrition News - Jul 03 2014]
TG Therapeutics Completes Global Licensing Agre... [Published GlobeNewswire: Advertising News - Jun 24 2014]
TG Therapeutics' TG-1101 (Ublituximab) in Combi... [Published GlobeNewswire: Acquisitions News - Jun 13 2014]
1 2 3
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.